Buoyed by rising generics sales across all three of its geographical regions as well as higher turnover from branded assets such as Austedo (deutetrabenazine) and Ajovy (fremanezumab), Teva has hiked its full-year revenues forecast by $100m to a range of $15.1bn-$15.5bn.
Key Takeaways
-
Amid generics growth across all regions and success with branded assets, Teva has added $100m to its full-year sales forecast, taking it to $15.1bn-$15.5bn.
“We’ve grown our generics business across all of our regions, US included,” highlighted Teva president and CEO Richard Francis as...







